US FDA Transparency Win: Sponsors Know More Product-Specific Guidances Coming, Requests Fall

 
• By Derrick Gingery

After creating a list of anticipated product-specific guidances to be published for generic sponsors and increasing PSG production, public requests for the agency to write a PSG declined.

transparency
Generic drug sponsors use the anticipated PSG list to validate development portfolios. • Source: Shutterstock

More from Generics

More from Biosimilars & Generics